Tofacitinib (CP-690550,Tasocitinib)

Licensed by Pfizer Catalog No.S2789

Tofacitinib (CP-690550,Tasocitinib) Chemical Structure

Molecular Weight(MW): 312.37

Tofacitinib (CP-690550,Tasocitinib) is a novel inhibitor of JAK3 with IC50 of 1 nM in cell-free assays, 20- to 100-fold less potent against JAK2 and JAK1.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 90 In stock
USD 270 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 48 Publications

Purity & Quality Control

Choose Selective JAK Inhibitors

Biological Activity

Description Tofacitinib (CP-690550,Tasocitinib) is a novel inhibitor of JAK3 with IC50 of 1 nM in cell-free assays, 20- to 100-fold less potent against JAK2 and JAK1.
Targets
JAK3 [1]
(Cell-free assay)
JAK2 [1]
(Cell-free assay)
JAK1 [1]
(Cell-free assay)
1 nM 20 nM 112 nM
In vitro

CP-690550 is a specific, orally inhibitor of JAK3, it is 20- to 100-fold less potent for JAK2 and JAK1 with IC50 of 20 nM and 112 nM, respectively. CP-690550 doesn't have potent activity against 30 other kinases (all median IC50 > 3000 nM). CP-690,550 inhibits IL-2–induced proliferation with 30-fold greater potency than its effects on GM-CSF–induced proliferation. [1] CP-690550 effectively inhibits a murine mixed lymphocyte reaction (MLR) (IC50 = 91 nM). [2] CP-690550 potently inhibits IL-4 induced upregulation of CD23 (IC50=57 nM) and class II major histocompatibility complex (MHCII) expression (IC50=71 nM) on murine B cells. [3] A recent research indicates low dose of CP-690550 accelerates the onset of experimental autoimmune encephalomyelitis by potentiating Th17 differentiation. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
CD4+ T  MV3GeY5kfGmxbjDBd5NigQ>? MV[yNE8yODBxNUCwJI5O NHv6TVA1QCCq NYHZeHg1cW6qaXLpeJMhfGinIHzleoVteyCxZjCgTWwuPCxiSV\OMe6{NCCLTD2xO2Eh[W6mIFnMMVIz NXXKRlU1OjF6OES1PFA>
CD4+ T  NWLDVnRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PvOFExOC93MECgcm0> MkXLOFghcA>? MVXpcohq[mm2czDhcpRqNUOGMz3pcoR2[2WmIFPEOEvDqFRiY3XscEBxem:uaX\ldoF1cW:w NXrESokyOjF6OES1PFA>
CD4+ T  M2m2d2Z2dmO2aX;uJGF{e2G7 NWrLb2VuOTByIH7N MYOyOE81QCCq MlXHZYJzd2ejdHXzJGNFOy2rbnT1Z4VlKHCqb4PwbI9zgWyjdHnvckBw\iCVVFHUdy=> NEDCeGEzOTh6NEW4NC=>
T cells MWfGeY5kfGmxbjDBd5NigQ>? NYr4Z2NJOC5zL{CuN{8yKM7:TR?= NVjxfVNFOjRiaB?= NUnsZ2lw\Gm|coXweJMh|rOlLXPoZYlvKGO7dH;rbY5mKHOrZ37hcIlv\w>? M1jWfFIyOzh|MkSx

... Click to View More Cell Line Experimental Data

In vivo In a murine model of heterotopic heart transplantation (DBA2 donor heart into C57/BL6 host), CP-690550 results in a dose-dependent increase in survival of transplanted hearts.The EC50 (drug concentration in blood at which 50% of mice will maintain their graft for >28 days) to be ~60 ng/mL.CP-690550 prevents rejection of allogeneic kidneys in nonhuman primate (NHPs, macaca fascicularis) (MST of 62 and 83 days for the 50 to 100 ng/ml groups and 200 to 400 ng/ml groups, respectively). [1] Mice chronically dosed with CP-690550 (1.5-15 mg/kg/day) demonstrates dose and time-dependent alterations in lymphocyte subsets when examined by flow cytometry. The most dramatic change observed is a 96% reduction in splenic NK1.1+TCRb-cell numbers following 21 days of treatment. Delayed-type hypersensitivity (DTH) responses in sensitized mice are reduced in a dose-dependent manner following treatment with CP-690550 (1.87–30 mg/kg, s.c.). Extended survival of neonatal Balb/c hearts implanted into the ear pinna of MHC mismatched C3H/HEN mice is observed with CP-690550 monotherapy (10–30 mg/kg/day), but improved upon combination with cyclosporin (10 mg/kg/day). [2]

Protocol

Kinase Assay:

[1]

+ Expand

JAK3 Kinase Assay:

A fragment encoding the catalytic domain of human JAK3 (785aa to 1125aa, JH1 catalytic domain) is amplified by PCR from the full length cDNA and cloned into the EcoRI site of the baculovirus transfer vector pVL1393. Recombinant baculovirus is used to infect Sf9 (Spodoptera frugipedra) cells and recombinant GSTJAK3 fusion protein is isolated on glutathione sepharose. The fusion protein is eluted with reduced glutathione and stored in buffer containing 50 mM Tris, pH 7.5, 10 mM DTT and 10% glycerol. JAK3 kinase activity is measured by ELISA as follows: Plates are coated overnight with a random L-glutamic acid and tyrosine co-polymer (4:1) (100 ug/mL). The plates are washed and recombinant JAK3 JH1:GST (100 ng/well) with or without inhibitors is incubated at room temperature for 30 minutes, after which HRP-conjugated PY20 anti-phosphotyrosine antibody (ICN) is added and developed by TMB (3,3',5,5'-tetramethylbenzidine). Other kinases (Table 1) are produced in E. coli or in insect cells, depending upon what is found to be optimal for the given kinase. The catalytic activity of tyrosine kinases is easured using the aftorementioned ELISA, whereas serine/threonine kinases are assayed using radioactive enzyme assays.
Cell Research:

[1]

+ Expand
  • Cell lines: Human T blasts cell
  • Concentrations: 0-4000 nM
  • Incubation Time: 4 days
  • Method:

    To measure IL-2-dependent proliferation, isolated lymphocytes are resuspended to a cell density of 1-2 × 106/mL in complete RPMI medium (RPMI 1640 containing 10% (w/v) fetal calf serum (FCS), 1%(w/v) penicillin and treptomycin).Phytohemagluttinin (PHA) is added to a final concentration of 10mg/mL, and the culture incubated for 3 days at 37 °C in a humidified 5% (v/v) CO2 incubator to upregulate IL-2R and JAK3 expression. IL-2 (200U/mL), with or without CP-690,550 is then added and the cells are incubated for 72 hours at 37 °C in a humidified 5% (v/v) CO2 incubator, after which 50 mL of 3H-thymidine (5mCi/mL) is added. The plates are incubated for an additional 18 hours, harvested with a 96-well harvester, and counted on a scintillation counter. HUO3 cells are maintained in culture with granulocyte-macrophage colony stimulating factor and human foreskin fibroblasts are maintained in culture with 10% fetal calf serum. CP-690550 is added to freshly plated cells and cultured for 4 days. 3Hthymidine is added during the last 18 hours of the culture period.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: DBA/2 and C57/BL6 mice
  • Formulation: CP-690550 is dissolved in polyethylene glycol 300.
  • Dosages: 0-136 ng/mL
  • Administration: Administered via osmotic minipump infusion
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 62 mg/mL warmed (198.48 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 312.37
Formula

C16H20N6O

CAS No. 477600-75-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03793439 Not yet recruiting Sarcoidosis Pulmonary|Sarcoidosis Lung|Sarcoidosis Oregon Health and Science University|Pfizer March 1 2019 Phase 1
NCT03793439 Not yet recruiting Sarcoidosis Pulmonary|Sarcoidosis Lung|Sarcoidosis Oregon Health and Science University|Pfizer March 1 2019 Phase 1
NCT03868072 Recruiting Rheumatoid Arthritis Chong Kun Dang Pharmaceutical February 22 2019 Phase 1
NCT03868072 Recruiting Rheumatoid Arthritis Chong Kun Dang Pharmaceutical February 22 2019 Phase 1
NCT03800979 Recruiting Alopecia Areata Institute of Dermatology Thailand January 12 2019 Phase 4
NCT03598959 Not yet recruiting Extranodal NK/T-cell Lymphoma Sichuan University January 1 2019 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I was just wondering what the main differences between S2789 and S5001?

  • Answer:

    S2789(Tofacitinib (CP-690550)) is the base form of S5001 (Tofacitinib (CP-690550) Citrate). The biological activity of these two compounds are same. The S5001 (Tofacitinib (CP-690550) Citrate) is more suitable for oral administration.

JAK Signaling Pathway Map

JAK Inhibitors with Unique Features

Related JAK Products4

Tags: buy Tofacitinib (CP-690550,Tasocitinib) | Tofacitinib (CP-690550,Tasocitinib) supplier | purchase Tofacitinib (CP-690550,Tasocitinib) | Tofacitinib (CP-690550,Tasocitinib) cost | Tofacitinib (CP-690550,Tasocitinib) manufacturer | order Tofacitinib (CP-690550,Tasocitinib) | Tofacitinib (CP-690550,Tasocitinib) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID